Nathan Weinstein
Stock Analyst at Aegis Capital
(0.32)
# 4,072
Out of 4,761 analysts
61
Total ratings
14.52%
Success rate
-24.61%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $1.42 | +5,545.73% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $20 → $15 | $0.69 | +2,073.91% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.55 | +985.97% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $40 → $35 | $1.27 | +2,655.91% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $2.20 | +172.73% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.15 | +1,295.35% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $4.60 | +117.39% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $17.68 | +177.15% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $5,250 → $150 | $1.36 | +10,929.41% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $4.27 | +50,485.48% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $1.71 | +1,654.39% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $0.87 | +1,047.32% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $21.54 | +642.80% | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $23.52 | +138.10% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $1.99 | +1,256.78% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $1.07 | +3,171.03% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.10 | +471.43% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $11.95 | +527.62% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $0.84 | +1,211.08% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $2.93 | +6,043.34% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $9 | $0.55 | +1,541.14% | 3 | Aug 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.02 | +178.88% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $0.59 | +1,767.26% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $3.08 | +175.97% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.42
Upside: +5,545.73%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $20 → $15
Current: $0.69
Upside: +2,073.91%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.55
Upside: +985.97%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $1.27
Upside: +2,655.91%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $2.20
Upside: +172.73%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.15
Upside: +1,295.35%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $4.60
Upside: +117.39%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $17.68
Upside: +177.15%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $5,250 → $150
Current: $1.36
Upside: +10,929.41%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $4.27
Upside: +50,485.48%
Dec 7, 2021
Initiates: Buy
Price Target: $30
Current: $1.71
Upside: +1,654.39%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $0.87
Upside: +1,047.32%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $21.54
Upside: +642.80%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $23.52
Upside: +138.10%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $1.99
Upside: +1,256.78%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $1.07
Upside: +3,171.03%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $2.10
Upside: +471.43%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $11.95
Upside: +527.62%
Oct 19, 2020
Maintains: Buy
Price Target: $13 → $11
Current: $0.84
Upside: +1,211.08%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $2.93
Upside: +6,043.34%
Aug 3, 2020
Maintains: Buy
Price Target: $13 → $9
Current: $0.55
Upside: +1,541.14%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $5.02
Upside: +178.88%
May 4, 2020
Maintains: Buy
Price Target: $9 → $11
Current: $0.59
Upside: +1,767.26%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $3.08
Upside: +175.97%